| advanced breast cancer (metastatic) | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| EMILIA, 2012 | vs lapatinib plus capecitabine | OS 0.68 [0.55; 0.85] PFS 0.65 [0.55; 0.77] | | | | TH3RESA, 2014 | vs lapatinib plus capecitabine | PFS 0.53 [0.42; 0.66] | | |
| Trial | Treatments | Patients | Method |
|---|
| EMILIA, 2012 | Trastuzumab emtansine (n=496) vs. lapatinib plus capecitabine (n=495) | patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane | Parallel groups Sample size: 496/495 Primary endpoint: FU duration: | | TH3RESA, 2014 | trastuzumab emtansine (n=404) vs. physician's choice (n=198) | patients with progressive HER2-positive advanced breast cancer who had received two or more HER2-directed regimens in the advanced setting | open-label Parallel groups Sample size: 404/198 Primary endpoint: progression-free survival (PFS) and overall survival FU duration: |
|
